A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Conditions:		Parkinson's Disease Psychosis
Purpose:		To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Study Summary:
Criteria:		Inclusion Criteria: - Subject has completed the treatment period of a previous blinded study of pimavanserin - The subject is willing and able to provide consent - Caregiver is willing and able to accompany the subject to all visits Exclusion Criteria: - Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder - Subject is judged by the Investigator to be inappropriate for the study
NCT ID:		NCT00550238
Primary Contact:		Mary Aloisio Phone: 858-320-8620 Email: maloisio@acadia-pharm.com
Backup Contact:		N/A
Location Contact:		Greensburg, Pennsylvania 15601 United States *There is no listed contact information for this specific location.* Site Status: Recruiting

Data Source:		ClinicalTrials.gov
Date Processed:		May 24, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.